A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Recruiting now · Phase 2
Conditions studied: Pulmonary Hypertension
In brief
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
Key facts
- Study ID
- NCT07073820
- Run by
- Pfizer
- People needed
- 36
- Starts
- 2025-11-10
- Expected to finish
- 2028-07-18
- Last updated by the study team
- 2026-05-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hammersmith Hospital — London, Greater London, United Kingdom (enrolling)
- UCSF Health St. Mary's Hospital — San Francisco, California, United States (enrolling)
- Heart and Vascular Center — San Francisco, California, United States (enrolling)
- University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States (enrolling)
- Norton Hospital — Louisville, Kentucky, United States (enrolling)
- Norton Pulmonary Specialists — Louisville, Kentucky, United States (enrolling)
- Gachon University Gil Medical Center — Incheon, Incheon-gwangyeoksi [incheon], South Korea (enrolling)
- Seoul National University Hospital — Seoul, Seoul-teukbyeolsi [seoul], South Korea (enrolling)
- Severance Hospital, Yonsei University Health System — Seoul, Seoul-teukbyeolsi [seoul], South Korea (enrolling)
- Samsung Medical Center — Seoul, Seoul-teukbyeolsi [seoul], South Korea (enrolling)
- Hospital Universitario Marques de Valdecilla — Santander, Cantabria, Spain (enrolling)
- Hospital Universitario La Paz — Madrid, Madrid, Comunidad de, Spain (enrolling)
- Hospital Universitario 12 de Octubre — Madrid, Spain (enrolling)
- Clinical Trials Unit at Eastowne Medical Office Building — Chapel Hill, North Carolina, United States (enrolling)
- Pulmonary Hypertension Clinical Trials Office at Eastowne — Chapel Hill, North Carolina, United States (enrolling)
- Pulmonary Specialty Clinic at Eastowne Medical Office Building — Chapel Hill, North Carolina, United States (enrolling)
- UNC Hospitals — Chapel Hill, North Carolina, United States (enrolling)
- Rhode Island Hospital — Providence, Rhode Island, United States (enrolling)
- Center for Advanced Lung Care — Providence, Rhode Island, United States (enrolling)
- Royal Prince Alfred Hospital — Camperdown, New South Wales, Australia (enrolling)
- Pulmonary Hypertension Research Queensland Pty Ltd — Auchenflower, Queensland, Australia (enrolling)
- HUB Hôpital Erasme — Brussels, Belgium (enrolling)
- UZ Leuven — Leuven, Belgium (enrolling)
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)
- The Second Xiangya Hospital of Central South University — Changsha, Hunan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.